Embryo assessment and selection is a critical step in an in vitro fertilization (IVF) procedure. Current embryo assessment approaches such as manual microscopy analysis done by embryologists or semi-automated time-lapse imaging systems are highly subjective, time-consuming, or expensive. Availability of cost-effective and easy-to-use hardware and software for embryo image data acquisition and analysis can significantly empower embryologists towards more efficient clinical decisions both in resource-limited and resource-rich settings. Here, we report the development of two inexpensive (<$100 and <$5) and automated imaging platforms that utilize advances in artificial intelligence (AI) for rapid, reliable, and accurate evaluations of embryo morphological qualities. Using a layered learning approach, we have shown that network models pre-trained with high quality embryo image data can be re-trained using data recorded on such low-cost, portable optical systems for embryo assessment and classification when relatively low-resolution image data are used. Using two test sets of 272 and 319 embryo images recorded on the reported stand-alone and smartphone optical systems, we were able to classify embryos based on their cell morphology with >90% accuracy.
The fundamental test for male infertility, semen analysis, is mostly a manually performed subjective and time-consuming process and the use of automated systems has been cost prohibitive. We have previously developed an inexpensive smartphone-based system for at-home male infertility screening through automatic and rapid measurement of sperm concentration and motility. Here, we assessed the feasibility of using a similar smartphone-based system for laboratory use in measuring: a) Hyaluronan Binding Assay (HBA) score, a quantitative score describing the sperm maturity and fertilization potential in a semen sample, b) sperm viability, which assesses sperm membrane integrity, and c) sperm DNA fragmentation that assesses the degree of DNA damage. There was good correlation between the manual analysis and smartphone-based analysis for the HBA score when the device was tested with 31 fresh, unprocessed human semen samples. The smartphone-based approach performed with an accuracy of 87% in sperm classification when the HBA score was set at manufacturer’s threshold of 80. Similarly, the sperm viability and DNA fragmentation tests were also shown to be compatible with the smartphone-based system when tested with 102 and 47 human semen samples, respectively.
13 August 2022 in Journal of Assisted Reproduction and Genetics
Viral hepatitis remains a major global health issue, with chronic hepatitis B (HBV) and hepatitis C (HCV) causing approximately 1 million deaths annually, primarily due to liver cancer and cirrhosis. More than 1.5 million people contract HCV each year, disproportionately affecting vulnerable populations, including American Indians and Alaska Natives (AI/AN). While direct-acting antivirals (DAAs) are highly effective, timely and accurate HCV diagnosis remains a challenge, particularly in resource-limited settings. The current two-step HCV testing process is costly and time-intensive, often leading to patient loss before treatment. Point-of-care (POC) HCV antigen (Ag) testing offers a promising alternative, but no FDA-approved test meets the required sensitivity and specificity. To address this, we developed a fully automated, smartphone-based POC HCV Ag assay using platinum nanoparticles, deep learning image processing, and microfluidics. With an overall accuracy of 94.59%, this cost-effective, portable device has the potential to reduce HCV-related health disparities, particularly among AI/AN populations, improving accessibility and equity in care.